Heron Therapeutics Dirección

Dirección controles de criterios 2/4

El CEO de Heron Therapeutics' es Craig Collard, nombrado en Apr 2023, tiene una permanencia de 1.33 años. posee directamente un 0.17% de las acciones de la empresa, con un valor de €425.72K. La antigüedad media del equipo directivo y de la junta directiva es de 1.3 años y 2.9 años, respectivamente.

Información clave

Craig Collard

Chief Executive Officer (CEO)

US$5.5k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.4yrs
Participación del CEO	0.2%
Permanencia media de la dirección	1.3yrs
Promedio de permanencia en la Junta Directiva	3yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Craig Collard (58 yo)

1.4yrs

Permanencia

US$5,486

Compensación

Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Collard	CEO & Director	1.4yrs	US$5.49k	0.17% $ 462.4k
Ira Duarte	Executive VP & CFO	1.3yrs	US$1.76m	0.069% $ 192.1k
William Forbes	Executive VP & Chief Development Officer	1.3yrs	US$1.71m	0.065% $ 183.2k
Ryan Craig	Vice President of Marketing	1.1yrs	sin datos	sin datos
Sean Ristine	Senior Vice President of Human Resources	9yrs	sin datos	sin datos
Robert Sullivan	Senior Vice President of Oncology Care Franchise & Commercial Operations	1.7yrs	sin datos	sin datos
Brett Fleshman	Chief Business Officer	no data	sin datos	sin datos
Jeff Cohn	Executive Director	no data	sin datos	sin datos

1.3yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AXD2 no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Craig Collard	CEO & Director	1.6yrs	US$5.49k	0.17% $ 462.4k
Craig Johnson	Independent Director	10.7yrs	US$11.02m	0.034% $ 95.7k
Christian Waage	Independent Director	8.3yrs	US$70.51k	0.034% $ 96.4k
Susan Rodriguez	Independent Director	3yrs	US$65.63k	0.035% $ 97.7k
Adam Morgan	Independent Chairman	1.6yrs	US$545.53k	0.0062% $ 17.5k
Sharmila Dissanaike	Independent Director	3yrs	US$55.00k	0.035% $ 97.7k

3.0yrs

Permanencia media

57.5yo

Promedio de edad

Junta con experiencia: La junta directiva de AXD2 se considera experimentada (3 años de antigüedad promedio).

Heron Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought €127k worth of stock

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Recent updates

Heron Therapeutics, Inc. Appoints Brett Fleshman as Chief Business Officer

Second quarter 2024 earnings released: US$0.061 loss per share (vs US$0.35 loss in 2Q 2023)

Heron Therapeutics, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Heron Therapeutics, Inc. Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System

Heron Therapeutics, Inc. Announces Acceptance of the Prior Approval Supplement Application for Zynrelef® Vial Access Needle

Heron Therapeutics, Inc. Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")

Forecast breakeven date moved forward to 2025

First quarter 2024 earnings released: US$0.021 loss per share (vs US$0.28 loss in 1Q 2023)

Heron Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

Heron Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Heron Therapeutics, Inc. Re-Affirms Earnings Guidance for the Full Year 2024

Full year 2023 earnings released: US$0.80 loss per share (vs US$1.67 loss in FY 2022)

Heron Therapeutics, Inc. to Report Q4, 2023 Results on Mar 12, 2024

Heron Therapeutics, Inc. Announces FDA Approval of ZYNRELEF® Indication Expansion to Include Additional Orthopedic and Soft Tissue Procedures

Forecast to breakeven in 2026

Kevin Kotler Resigns as A Member of the Board of Directors of Heron Therapeutics, Inc., Effective December 31, 2023

CEO & Director recently bought €127k worth of stock

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.38 loss in 3Q 2022)

Heron Therapeutics, Inc. Provides Financial Guidance for the Year 2023 and 2024

Heron Therapeutics, Inc. to Report Q3, 2023 Results on Nov 14, 2023

New minor risk - Market cap size

Second quarter 2023 earnings released: US$0.35 loss per share (vs US$0.55 loss in 2Q 2022)

Heron Therapeutics, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Heron Therapeutics, Inc. Announces Resignation of David Szekeres as Executive Vice President, Chief Operating Officer of the Company

Heron Therapeutics Announces Appointment of Ira Duarte as Chief Financial Officer

Heron Therapeutics Announces Appointment of William Forbes, Pharm.D. as Executive Vice President and Chief Development Officer

Heron Therapeutics, Inc. Announces Management Changes

First quarter 2023 earnings released: US$0.28 loss per share (vs US$0.63 loss in 1Q 2022)

Heron Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

No longer forecast to breakeven

Full year 2022 earnings released: US$1.67 loss per share (vs US$2.24 loss in FY 2021)

High number of new directors

Rubric Capital Management Engages with Heron Therapeutics

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2023

Forecast to breakeven in 2025

Heron Therapeutics, Inc. Announces the Submission of Supplemental New Drug Application for ZYNRELEF

Third quarter 2022 earnings released: US$0.38 loss per share (vs US$0.51 loss in 3Q 2021)

Heron Therapeutics, Inc. Provides Sales Guidance for the Year 2022

Heron Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Heron Therapeutics, Inc. Announces U.S. FDA Approval of APONVIE™ (HTX-019) for Prevention of Postoperative Nausea and Vomiting

Heron Therapeutics, Inc. announced that it has received $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC

Second quarter 2022 earnings released: US$0.55 loss per share (vs US$0.62 loss in 2Q 2021)

Heron Therapeutics, Inc. announced that it expects to receive $76.499144 million in funding from Deep Track Capital, LP, Great Point Partners, LLC, Broadfin Holdings LLC and other investors

Heron Therapeutics, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

Heron Therapeutics, Inc. to Report Q1, 2022 Results on May 09, 2022

Heron Therapeutics, Inc., Annual General Meeting, May 24, 2022

Heron Therapeutics, Inc. Does Not Provide Financial Guidance for the Full Year 2022

Heron Therapeutics, Inc. to Report Q4, 2021 Results on Feb 28, 2022

Forecast to breakeven in 2024

Heron Therapeutics, Inc. Announces FDA Approval of a Significant Indication Expansion for ZYNRELEF

Third quarter 2021 earnings released: US$0.51 loss per share (vs US$0.64 loss in 3Q 2020)

High number of new and inexperienced directors

High number of new and inexperienced directors

Second quarter 2021 earnings released: US$0.62 loss per share (vs US$0.61 loss in 2Q 2020)

No longer forecast to breakeven

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF for the Management of Postoperative Pain for up to 72 Hours

Heron Therapeutics, Inc. announced that it expects to receive $150 million in funding from Baker Bros. Advisors LP

Heron Therapeutics Receives Approval from U.S. Food and Drug Administration for ZYNRELEF

Heron Therapeutics Announces U.S. FDA Approval of ZYNRELEF™ (HTX-011) for the Management of Postoperative Pain for up to 72 Hours

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.57 loss in 1Q 2020)

Heron Therapeutics, Inc. Provides Sales Guidance for the Full Year 2021

Revenue beats expectations

Full year 2020 earnings released: US$2.50 loss per share (vs US$2.50 loss in FY 2019)

Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery

Heron Therapeutics, Inc. Highlights Progress in Pain Management and CINV Franchises and Announces New Development Program

New 90-day high: €16.85

Heron Therapeutics, Inc. Announces Resubmission of NDA to the U.S. Food and Drug Administration (FDA) for HTX-011